TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M

Stock Information for TScan Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TScan Therapeutics Inc.

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.